← All trials
NCT05904028
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 9, 2023
- Primary completion
- Jul 30, 2027
- Completion date
- Jul 30, 2027
- First posted
- Jun 15, 2023
- Last posted
- Sep 28, 2023
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jaeb Center for Health ResearchLead sponsor
- National Institutes of Health (NIH)Collaborator
- National Eye Institute (NEI)Collaborator
- Juvenile Diabetes Research FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.